AdvisorShares Psychedelics ETF—— (—)Compass Pathways—— (—)Definium Therapeutics—— (—)GH Research—— (—)Helus Pharma—— (—)MIRA Pharmaceuticals—— (—)Neuphoria Therapeutics—— (—)Eli Lilly—— (—)Johnson & Johnson—— (—)AbbVie—— (—)Otsuka Pharmaceutical—— (—)Numinus Wellness—— (—)Optimi Health—— (—)PharmAla Biotech—— (—)Enveric Biosciences—— (—)Incannex Healthcare—— (—)Aurora Cannabis—— (—)Cronos Group—— (—)SNDL—— (—)Bright Minds Biosciences—— (—)PharmaTher Holdings—— (—)IM Cannabis—— (—)MariMed—— (—)Vireo Growth—— (—)

Loading prices

Clinicaltrialvanguard

Published November 12, 2026

Capricor Files Q3 2026 Results Before Deramiocel FDA Decision

Read the full story at Clinicaltrialvanguard

Psychedelic Clinical Trials PSYCH PULSE Real-World Evidence site ... The 8-K itself is a bare procedural filing: it references a press release.

Post on X

Share this story

Surfaced by this Google Alert

Psychedelic press release